# Gerald W. Prager

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/gerald-w-prager/

## Facts

| Field | Value |
| --- | --- |
| Citations | 6,751 |
| Field | Colorectal Cancer Treatments and Studies |
| h-index | 44 |
| i10-index | 97 |
| Last Known Institution | Medical University of Vienna |
| OpenAlex ID | https://openalex.org/A5034847353 |
| ORCID iD | 0000-0002-7854-7781 |
| Works | 390 |

## Researcher papers

- [Pancreatic cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up](https://scholariq.org/papers/pancreatic-cancer-esmo-clinical-practice-guideline-for-diagnosis-treatment-and/)
- [Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial](https://scholariq.org/papers/dabrafenib-plus-trametinib-in-patients-with-brafv600e-mutated-biliary-tract/)
- [Trifluridine–Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer](https://scholariq.org/papers/trifluridine-tipiracil-and-bevacizumab-in-refractory-metastatic-colorectal/)
- [uPAR – uPA – PAI-1 interactions and signaling: A vascular biologist’s view](https://scholariq.org/papers/upar-upa-pai-1-interactions-and-signaling-a-vascular-biologist-s-view/)
- [Plasminogen Activator Inhibitor 1: Physiological and Pathophysiological Roles](https://scholariq.org/papers/plasminogen-activator-inhibitor-1-physiological-and-pathophysiological-roles/)
- [Functional Precision Medicine Provides Clinical Benefit in Advanced Aggressive Hematologic Cancers and Identifies Exceptional Responders](https://scholariq.org/papers/functional-precision-medicine-provides-clinical-benefit-in-advanced-aggressive/)
- [Image-based ex-vivo drug screening for patients with aggressive haematological malignancies: interim results from a single-arm, open-label, pilot study](https://scholariq.org/papers/image-based-ex-vivo-drug-screening-for-patients-with-aggressive-haematological/)
- [PET/MRI versus PET/CT in oncology: a prospective single-center study of 330 examinations focusing on implications for patient management and cost considerations](https://scholariq.org/papers/pet-mri-versus-pet-ct-in-oncology-a-prospective-single-center-study-of-330/)
- [Integrins in the Spotlight of Cancer](https://scholariq.org/papers/integrins-in-the-spotlight-of-cancer/)
- [Simvastatin Reduces the Expression of Adhesion Molecules in Circulating Monocytes From Hypercholesterolemic Patients](https://scholariq.org/papers/simvastatin-reduces-the-expression-of-adhesion-molecules-in-circulating/)
- [Update on esophageal function, acid and non-acid reflux after one-anastomosis gastric bypass (OAGB): high-resolution manometry, impedance-24-h pH-metry, and gastroscopy in a prospective mid-term study](https://scholariq.org/papers/update-on-esophageal-function-acid-and-non-acid-reflux-after-one-anastomosis/)

## Researcher topics

- [Colorectal Cancer Treatments and Studies](https://scholariq.org/topics/colorectal-cancer-treatments-and-studies/)
- [Cancer Treatment and Pharmacology](https://scholariq.org/topics/cancer-treatment-and-pharmacology/)
- [Pancreatic and Hepatic Oncology Research](https://scholariq.org/topics/pancreatic-and-hepatic-oncology-research/)
- [Gastric Cancer Management and Outcomes](https://scholariq.org/topics/gastric-cancer-management-and-outcomes/)
- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)

## Researcher university

- [Medical University of Vienna](https://scholariq.org/institutions/medical-university-of-vienna/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.